Loading clinical trials...

Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast) | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNANCT06925984

Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)

The Oligopro-Breast trial is a Phase II study targeting women with ER+/HER2- metastatic breast cancer who have been on endocrine therapy and/or CDK4/6 inhibitors for at least 6 months, and show progre...

Lead sponsor: Jules Bordet Institute•5 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Robbe Van den Begin, MD PhD

CONTACT

+32 2 541 38 28 [email protected]

Related studies

RECRUITINGNA

Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma

NCT07112170 · Metastatic Melanoma, OligoProgressive Metastatic Disease

Not Yet RecruitingPhase 2

ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)

NCT06813664 · Metastatic NSCLC - Non-Small Cell Lung Cancer, OligoProgressive Metastatic Disease

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 2, 2026Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment48

Start dateOct 2025

Last updatedFeb 2, 2026

Condition

OligoProgressive Metastatic Disease

Locations shown

Jules Bordet Institute

Brussels

UZ Gent

Ghent

AZ Groeninge

Kortrijk

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 2, 2026Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions